U.S.S.N. 10/810,767 Examiner: D. Rao Attorney Docket No.: CCI-029CN Group Art Unit: 1624

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

```
1.
       (Currently Amended)
                                    A compound selected from the group consisting of:
[4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(3-nitro-phenyl)-amine [1];
N-[4-(2-Amino 4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-N',N'-dimethyl-benzene-1,4-
diamine [2];
[4-(2-Amino 4 methyl-thiazol 5-yl)-pyrimidin 2-yl]-(4-chloro-phenyl) amine [3];
[4-(2-Amino 4-methyl thiazol 5-yl) pyrimidin-2-yl]-(3-methoxy-phenyl) amine [4];
[4-(2-Amino 4 methyl thiazol-5-yl) pyrimidin-2-yl]-(3-fluoro-phenyl) amine [5];
[4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(4-trifluoromethyl-phenyl)-amine
[7];
[4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(4-methoxy-phenyl)-amine [8];
[4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(3-chloro-phenyl)-amine [9];
[4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(3-iodo-phenyl)-amine [10];
[4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(4-iodo-phenyl)-amine [11];
[4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(4-fluoro-phenyl)-amine [12];
3-[4 (2-Amino 4-methyl-thiazol-5-yl) pyrimidin 2-ylamino] phenol [13];
[4-(2-Amino-4-methyl-thiazol-5-yl) pyrimidin-2-yl] (4-iodo-3-nitro-phenyl) amine [14];
2-{4-[4-(2-Amino-4-methyl thiazol-5-yl)-pyrimidin-2-ylamino]-phenyl}-ethanol-[15];
[4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(3-bromo-phenyl)-amine [16];
[4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(4-bromo-phenyl)-amine [17];
[4 (2 Amino 4 methyl thiazol-5-yl) pyrimidin 2-yl] (4-chloro-3-trifluoromethyl-phenyl)
amine [18];
N<sup>1</sup>-[4-(2,4-Dimethyl-thiazol-5-yl)-pyrimidin-2-yl]-4-[β-(phenoxy)-triethylamine] amine
\{20\};
2-{4-[4-(2,4-Dimethyl-thiazol-5-yl)-pyrimidin-2-ylamino]-phenyl}-ethanol-[21];
2-({4-[4-(2,4-Dimethyl-thiazol-5-yl) pyrimidin 2-ylamino]-phenyl} ethyl-amino)-
ethanol [22];
(3,4 Dimethoxy phenyl) [4-(2,4 dimethyl-thiazol 5-yl) pyrimidin 2-yl] amine [23];
5-[4-(2,4-Dimethyl thiazol-5-yl) pyrimidin-2 ylamino] 2-methoxy-phenol [24];
```

Examiner: D. Rao Group Art Unit: 1624

- N⁴-[4-(2,4 Dimethyl thiazol-5-yl) pyrimidin-2-yl]-N¹,N¹-dimethyl-2-nitro benzene-1,4-diamine [25];
- 2-[N (4-N,N-Dimethylamino-3-chlorophenyl)]-4 (2,4-dimethylthiazol-5-yl)-pyrimidineamine [26];
- N⁴-[4-(2,4-Dimethyl-thiazol-5-yl) pyrimidin-2-yl] N¹,N¹-dimethyl-2-trifluoromethyl-benzene-1,4-diamine [27];
- N¹-[4 (2,4-Dimethyl thiazol-5-yl) pyrimidin 2-yl] 4 methoxy N²,N³-dimethyl benzene-1,3-diamine [28];
- N,N-Dimethyl N' [4 (4-methyl-2-methylamino-thiazol-5-yl) pyrimidin 2-yl] benzene-1,4-diamine [29];
- (4-Iodo-3-nitro-phenyl) [4 (4-methyl-2-methylamino-thiazol-5-yl) pyrimidin-2-yl]-amine 1301:
- 4-[4-(2 Methoxy-4-methyl-thiazol-5-yl)-pyrimidin-2-ylamino]-phenol [31];
- [4-(2-Methoxy 4-methyl-thiazol-5-yl)-pyrimidin-2-yl] (3-nitro-phenyl) amine [32];
- (4-Iodo-phenyl) [4 (2-methoxy-4-methyl-thiazol-5-yl) pyrimidin-2-yl]-amine [33];
- (4-Fluoro-phenyl) [4-(2-methoxy-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-amine [34];
- (4 Chloro-phenyl)-[4 (2-methoxy-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-amine [35];
- [4 (2 Methoxy 4 methyl-thiazol-5-yl) pyrimidin 2-yl] (4 methoxy-phenyl) amine [36];
- 3-[4-(2 Methoxy-4-methyl-thiazol-5-yl) pyrimidin-2-ylamino]-phenol [37];
- (4-Fluoro-3 nitro-phenyl) [4 (2 methoxy-4 methyl-thiazol-5-yl) pyrimidin 2-yl] amine [38];
- (4 Chloro-3-methyl-phenyl) [4 (2-methoxy-4-methyl-thiazol-5-yl) pyrimidin 2-yl]-amine [39];
- (3-Iodo-4-methyl-phenyl) [4 (2-methoxy-4-methyl-thiazol-5-yl)-pyrimidin 2-yl]-amine [40];
- (4 Fluoro 3 methyl-phenyl) [4 (2 methoxy 4 methyl-thiazol 5 yl) pyrimidin 2 yl] amine [41];
- [4-(2 Methoxy 4 methyl thiazol 5 yl) pyrimidin 2 yl] (4 methyl 3 nitro phenyl) amine [42];
- N [4 (2 Methoxy 4 methyl thiazol 5 yl) pyrimidin 2 yl] N',N' dimethyl benzene 1,4-diamine [43];
- [4 (2 Ethylamino 4 methyl thiazol 5 yl) pyrimidin 2 yl] (3 nitro phenyl) amine [44];
- (4 Chloro-phenyl) [4 (2-ethylamino-4-methyl-thiazol-5-yl)-pyrimidin 2-yl]-amine [45];
- [4-(2 Ethylamino 4 methyl thiazol-5-yl) pyrimidin 2 yl] (4-trifluoromethyl phenyl) amine [47];

U.S.S.N. 10/810,767

Attorney Docket No.: CCI-029CN Group Art Unit: 1624

Examiner: D. Rao

- [4 (2 Ethylamino 4 methyl thiazol 5 yl) pyrimidin 2 yl] (3 methoxy phenyl) amine [48];
- (3-Chloro-phenyl) [4 (2-ethylamino 4-methyl thiazol 5-yl) pyrimidin 2-yl] amine [49]; [4 (2-Ethylamino 4-methyl-thiazol 5-yl) pyrimidin 2-yl] (4-methyl-3-nitro-phenyl) amine [50];
- [4 (2 Butylamino 4 methyl thiazol 5 yl) pyrimidin 2 yl] (4 fluoro phenyl) amine [51]; [4 (2 Dimethylamino 4 methyl thiazol 5 yl) pyrimidin 2 yl] (3 nitro phenyl) amine [52];
- (4-Chloro phenyl) [4-(2-dimethylamino 4-methyl-thiazol-5-yl) pyrimidin 2-yl] amine [53];
- [4 (2 Dimethylamino 4 methyl thiazol 5 yl) pyrimidin 2 yl] (4 fluoro phenyl) amine [54];
- (3 Chloro phenyl) [4 (2 dimethylamino 4 methyl thiazol 5 yl) pyrimidin 2 yl] amine [55];
- N-{4-Methyl-5-[2-(3-nitro-phenylamino)-pyrimidin-4-yl]-thiazol-2-yl}-methanesulfonamide [56];
- 2-{4-Methyl-5-[2-(3-nitro-phenylamino)-pyrimidin-4-yl]-thiazol-2-ylamino}-ethanol [58];
- 2-{5-[2-(4-Fluoro-phenylamino)-pyrimidin-4-yl]-4-methyl-thiazol-2-ylamino}-ethanol [59];
- 2-Chloro-N-{4-methyl-5-[2-(3-nitro-phenylamino)-pyrimidin-4-yl]-thiazol-2-yl}-acetamide [60];
- 2-Chloro-N-{5-[2-(4-fluoro-phenylamino)-pyrimidin-4-yl]-4-methyl-thiazol-2-yl}-acetamide [61];
- [4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(4-nitro-phenyl)-amine [63];
- [4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(phenyl)-amine [64]; and
- 4-[4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-benzenesulfonic acid [65]; or a pharmaceutically acceptable salt thereofand
- 4 [4 (2,4 Dimethyl-thiazol-5 yl)-pyrimidin-2-ylamino]-benzenesulfonic acid [66].
- 2. (Currently Amended) A compound according to claim 1, selected from the group consisting of:
- [4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(3-nitro-phenyl)-amine [1];
- [4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(3-chloro-phenyl)-amine [9];
- [4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(3-iodo-phenyl)-amine [10];

U.S.S.N. 10/810,767 Attorney Docket No.: CCI-029CN

diamine [25];

3-[4 (2-Amino-4 methyl-thiazol-5-yl) pyrimidin 2-ylamino] phenol [13];
[4 (2-Amino-4 methyl-thiazol-5-yl) pyrimidin 2-yl] (4-iodo-3 nitro-phenyl) amine [14];
[4 (2-Amino-4 methyl-thiazol-5-yl) pyrimidin 2-yl] (3-bromo-phenyl) amine [16];
(3,4-Dimethoxy-phenyl) [4 (2,4-dimethyl-thiazol-5-yl) pyrimidin 2-yl] amine [23];
N⁴-[4 (2,4-Dimethyl-thiazol-5-yl) pyrimidin 2-yl] N¹,N¹-dimethyl-2 nitro-benzene 1,4-

Examiner: D. Rao

Group Art Unit: 1624

- 2-[N (4-N,N Dimethylamino 3-chlorophenyl)] 4 (2,4-dimethylthiazol 5-yl)-pyrimidineamine [26];
- N,N-Dimethyl N' [4 (4 methyl 2 methylamino thiazol-5 yl) pyrimidin 2 yl] benzene 1,4 diamine [29];
- 4-[4 (2 Methoxy 4 methyl-thiazol-5-yl) pyrimidin-2 ylamino] phenol [31];
- [4 (2 Methoxy 4 methyl thiazol-5-yl) pyrimidin-2-yl] (3 nitro phenyl) amine [32];
- (4-Fluoro-phenyl) [4 (2-methoxy 4-methyl-thiazol-5-yl) pyrimidin-2-yl]-amine [34];
- [4-(2 Methoxy 4 methyl-thiazol-5-yl) pyrimidin-2-yl] (4 methyl-3 nitro phenyl) amine [42];
- N-{4-Methyl-5-[2-(3-nitro-phenylamino)-pyrimidin-4-yl]-thiazol-2-yl}-methanesulfonamide [56];
- 2-{4-Methyl-5-[2-(3-nitro-phenylamino)-pyrimidin-4-yl]-thiazol-2-ylamino}-ethanol [58];
- 2-Chloro-N-{4-methyl-5-[2-(3-nitro-phenylamino)-pyrimidin-4-yl]-thiazol-2-yl}-acetamide [60]; and
- 2-Chloro-N-{5-[2-(4-fluoro-phenylamino)-pyrimidin-4-yl]-4-methyl-thiazol-2-yl}-acetamide [61], or a pharmaceutically acceptable salt thereof.
- 3. (Currently Amended) A compound according to claim 2, selected from the group consisting of::
- 3-[4-(2-Amino 4 methyl-thiazol-5-yl)-pyrimidin-2-ylamino] phenol [13];
- [4-(2-Amino-4-methyl-thiazol-5-yl) pyrimidin-2-yl]-(4-iodo-3-nitro-phenyl) amine [14];
- (3,4 Dimethoxy phenyl) [4-(2,4 dimethyl-thiazol 5-yl) pyrimidin 2-yl] amine [23];
- N,N-Dimethyl N' [4 (4 methyl 2 methylamino thiazol 5 yl) pyrimidin 2 yl] benzene 1,4 diamine [29];
- (4 Fluoro phenyl) [4 (2 methoxy 4 methyl thiazol 5 yl) pyrimidin 2 yl] amine [34]; [4 (2 Methoxy 4 methyl thiazol 5 yl) pyrimidin 2 yl] (4 methyl 3 nitro phenyl) amine [42];

U.S.S.N. 10/810,767

Attorney Docket No.: CCI-029CN Group Art Unit: 1624

Examiner: D. Rao

2-Chloro-N-{4-methyl-5-[2-(3-nitro-phenylamino)-pyrimidin-4-yl]-thiazol-2-yl}-acetamide [60]; and 2-Chloro-N-{5-[2-(4-fluoro-phenylamino)-pyrimidin-4-yl]-4-methyl-thiazol-2-yl}-

acetamide [61], or a pharmaceutically acceptable salt thereof.

- 4. (Currently Amended) A compound according to claim 2, selected from the following:
- [4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(3-nitro-phenyl)-amine [1];
- [4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(3-chloro-phenyl)-amine [9];
- [4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(3-iodo-phenyl)-amine [10];
- [4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(3-bromo-phenyl)-amine [16];
- N⁴-[4-(2,4-Dimethyl-thiazol-5-yl) pyrimidin-2-yl] N¹,N¹-dimethyl-2-nitro-benzene-1,4-diamine [25];
- 2-[N (4-N,N-Dimethylamino-3-chlorophenyl)]-4 (2,4-dimethylthiazol-5-yl)-pyrimidineamine [26];
- 4-[4-(2-Methoxy-4-methyl-thiazol-5-yl) pyrimidin-2-ylamino] phenol [31];
- [4-(2 Methoxy-4 methyl-thiazol-5-yl)-pyrimidin-2-yl]-(3-nitro-phenyl) amine [32];
- $N-\{4-Methyl-5-[2-(3-nitro-phenylamino)-pyrimidin-4-yl]-thiazol-2-yl\}-10-(3-nitro-phenylamino)-pyrimidin-4-yl]-thiazol-2-yl\}-10-(3-nitro-phenylamino)-pyrimidin-4-yl]-thiazol-2-yl\}-10-(3-nitro-phenylamino)-pyrimidin-4-yl]-thiazol-2-yl\}-10-(3-nitro-phenylamino)-pyrimidin-4-yl]-thiazol-2-yl\}-10-(3-nitro-phenylamino)-pyrimidin-4-yl]-thiazol-2-yl\}-10-(3-nitro-phenylamino)-pyrimidin-4-yl]-thiazol-2-yl]-10-(3-nitro-phenylamino)-pyrimidin-4-yl]-10-(3-nitro-phenylamino)-pyrimidin-4-yl]-10-(3-nitro-phenylamino)-pyrimidin-4-yl]-10-(3-nitro-phenylamino)-pyrimidin-4-yl]-10-(3-nitro-phenylamino)-pyrimidin-4-yl]-10-(3-nitro-phenylamino)-pyrimidin-4-yl]-10-(3-nitro-phenylamino)-pyrimidin-4-yl]-10-(3-nitro-phenylamino)-pyrimidin-4-yl]-10-(3-nitro-phenylamino)-pyrimidin-4-yl]-10-(3-nitro-phenylamino)-pyrimidin-4-yl]-10-(3-nitro-phenylamino)-pyrimidin-4-yl]-10-(3-nitro-phenylamino)-pyrimidin-4-yl$

methanesulfonamide [56]; and

- 2-{4-Methyl-5-[2-(3-nitro-phenylamino)-pyrimidin-4-yl]-thiazol-2-ylamino}-ethanol [58] or a pharmaceutically acceptable salt thereof.
- 5. (Currently Amended) The compound of claim 4, wherein said compound is [4-(2-Methoxy-4-methyl-thiazol-5-yl) pyrimidin 2-yl] (3-nitro-phenyl) amine [32] or 2-{4-Methyl-5-[2-(3-nitro-phenyl amino)-pyrimidin-4-yl]-thiazol-2-ylamino}-ethanol [58] or a pharmaceutically acceptable salt thereof.
- 6. (Currently Amended) A compound selected from the group consisting of: [4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(3-nitro-phenyl)-amine [1]; [4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(4-trifluoromethyl-phenyl)-amine [7];
- [4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(4-methoxy-phenyl)-amine [8];
- [4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(3-chloro-phenyl)-amine [9];
- [4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(3-iodo-phenyl)-amine [10];
- [4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(4-iodo-phenyl)-amine [11];

Attorney Docket No.: CCI-029CN Group Art Unit: 1624

Examiner: D. Rao

- [4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(4-fluoro-phenyl)-amine [12];
- [4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(3-bromo-phenyl)-amine [16];
- [4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(4-bromo-phenyl)-amine [17];
- N-{4-Methyl-5-[2-(3-nitro-phenylamino)-pyrimidin-4-yl]-thiazol-2-yl}-methanesulfonamide [56];
- 2-{4-Methyl-5-[2-(3-nitro-phenylamino)-pyrimidin-4-yl]-thiazol-2-ylamino}-ethanol [58];
- 2-{5-[2-(4-Fluoro-phenylamino)-pyrimidin-4-yl]-4-methyl-thiazol-2-ylamino}-ethanol [59];
- 2-Chloro-N-{4-methyl-5-[2-(3-nitro-phenylamino)-pyrimidin-4-yl]-thiazol-2-yl}-acetamide [60];
- 2-Chloro-N-{5-[2-(4-fluoro-phenylamino)-pyrimidin-4-yl]-4-methyl-thiazol-2-yl}-acetamide [61];
- [4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(4-nitro-phenyl)-amine [63];
- [4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(phenyl)-amine [64]; and
- 4-[4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-benzenesulfonic acid [65]; or a pharmaceutically acceptable salt thereof and
- 4-[4 (2,4-Dimethyl thiazol-5-yl)-pyrimidin 2-ylamino] benzenesulfonic acid [66].
- 7. (**Currently Amended**) A compound according to claim 6 selected from the group consisting of:
- [4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(3-nitro-phenyl)-amine [1];
- [4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(3-chloro-phenyl)-amine [9];
- [4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(3-iodo-phenyl)-amine [10];
- [4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(3-bromo-phenyl)-amine [16];
- *N*-{4-Methyl-5-[2-(3-nitro-phenylamino)-pyrimidin-4-yl]-thiazol-2-yl}-methanesulfonamide [56];
- 2-{4-Methyl-5-[2-(3-nitro-phenylamino)-pyrimidin-4-yl]-thiazol-2-ylamino}-ethanol [58];
- 2-Chloro-N-{4-methyl-5-[2-(3-nitro-phenylamino)-pyrimidin-4-yl]-thiazol-2-yl}-acetamide [60]; and
- 2-Chloro-N-{5-[2-(4-fluoro-phenylamino)-pyrimidin-4-yl]-4-methyl-thiazol-2-yl}-acetamide [61]; or a pharmaceutically acceptable salt thereof.

U.S.S.N. 10/810,767 Examiner: D. Rao Attorney Docket No.: CCI-029CN Group Art Unit: 1624

8. (Currently Amended) A compound according to claim 7 which is selected from the group consisting of 2-Chloro-N-{4-methyl-5-[2-(3-nitro-phenylamino)-pyrimidin-4-yl]-thiazol-2-yl}-acetamide [60]; and 2-Chloro-N-{5-[2-(4-fluoro-phenylamino)-pyrimidin-4-yl]-4-methyl-thiazol-2-yl}-acetamide [61]; or a pharmaceutically acceptable salt thereof.

9. (Currently Amended) A compound according to claim 7 which is selected from the group consisting of:

[14. (2. Amino Amended) South and South Amended (3. Amino Amended) South Amended (4. Amino Amino Amended) South Amended (4. Amino Amino

[4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(3-nitro-phenyl)-amine [1];

[4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(3-chloro-phenyl)-amine [9];

[4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(3-iodo-phenyl)-amine [10];

[4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(3-bromo-phenyl)-amine [16];

N-{4-Methyl-5-[2-(3-nitro-phenylamino)-pyrimidin-4-yl]-thiazol-2-yl}-methanesulfonamide [56]; and

2-{4-Methyl-5-[2-(3-nitro-phenylamino)-pyrimidin-4-yl]-thiazol-2-ylamino}-ethanol [58]; or a pharmaceutically acceptable salt thereof.

10. (Currently Amended) A compound according to claim 9 which is selected from the group consisting of:

[4-(2-amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(3-nitro-phenyl)-amine [1];

N-{4-Methyl-5-[2-(3-nitro-phenylamino)-pyrimidin-4-yl]-thiazol-2-yl}-methanesulfonamide [56]; and

2-{4-Methyl-5-[2-(3-nitro-phenylamino)-pyrimidin-4-yl]-thiazol-2-ylamino}-ethanol [58]; or a pharmaceutically acceptable salt thereof.

- 11. (**Currently Amended**) A compound according to claim 9 which is [4-(2-Amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(3-nitro-phenyl)-amine [1]; or a pharmaceutically acceptable salt thereof.
- 12. (Original) A pharmaceutical composition comprising a compound according to claim 1 or 6, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable diluent, excipient or carrier.
- 13. (Original) A pharmaceutical composition according to claim 12 which further comprises one or more other anticancer agents.

U.S.S.N. 10/810,767 Examiner: D. Rao Attorney Docket No.: CCI-029CN Group Art Unit: 1624

14. (Original) A method for treating a proliferative disorder in a subject, comprising administering one or more compound of claim 1 or 6, or a pharmaceutically acceptable salt thereof, to a subject, such that the subject is treated for a proliferative disorder.

- 15. (**Original**) The method of claim 14, wherein the proliferative disorder is cancer or leukaemia.
- 16. (**Original**) The method of claim 14, wherein said one or more compounds are administered in an amount sufficient to inhibit at least one CDK enzyme.
- 17. (Original) The method of claim 16 wherein the CDK enzyme is CDK2 or CDK4.
- 18. (Cancelled).
- 19. (Currently Amended) Use according to The method of claim 1418, wherein said compound is administered in combination with one or more other anticancer agents.
- 20. (New) The method of claim 14, wherein said proliferative disorder is lung cancer.
- 21. (New) The method of claim 14, wherein said proliferative disorder is colon cancer.
- 22. (New) The method of claim 14, wherein said proliferative disorder is bone cancer.